Inhibrx Biosciences Inc.
INBX
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.37B
Close$
$0.81
99.1% downside
Current Fair Value
99.1% downsideOvervalued by 99.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.37 Billion |
|---|---|
| Enterprise Value | $1.25 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-9.04 |
| Beta | 3.82 |
| Outstanding Shares | 15,669,000 |
Return
| Return on Equity | 260.83% |
|---|---|
| Return on Assets | -89.60% |
| Return on Invested Capital | -100.40% |
Valuation & Multiples
| P/E Ratio | -10.52 |
|---|---|
| PEG | -37.68 |
| Price to Sales | - |
| Price to Book Ratio | -23.35 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -9.84 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | -0.1 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
$-1.90
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-2.45
Average shareholder expectationRevenue Estimate
$1.90 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 14.70% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.19%▼ 91.46% |
|---|---|
| Total Invested | $3.02M▼ 99.78% |
| Investors Holding | 11▼ 167.00% |
ESG Score
No data
About Inhibrx Inc
88 employeesInhibrx is a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. Inhibrx utilizes diverse methods of protein engineering to address the spe...